Form 4: QCLS Director & CMO Acquires 1,080 Shares via RSU Grant

Mitchell Glass, Director and Chief Medical Officer of Q/C Technologies, Inc., acquired 1,080 shares of common stock through an immediately vested Restricted Stock Unit grant.

Summary

• Mitchell Glass, serving as both a Director and Chief Medical Officer of Q/C Technologies, Inc. (QCLS), acquired 1,080 shares of the company's common stock.
• The acquisition occurred on October 3, 2025, and was a grant of Restricted Stock Units (RSUs).
• The RSUs vested immediately upon grant, meaning Mr. Glass now beneficially owns these shares directly.
• The transaction was reported on a Form 4 filing with the SEC on October 6, 2025.

Sentiment

Score: 7

Explanation: The acquisition of shares by a key insider, even through a grant, generally indicates increased alignment between management and shareholder interests, which is a positive signal. The immediate vesting further solidifies this alignment.

Positives

• The acquisition of shares by a key executive and director, Mitchell Glass, increases insider ownership, which can align management interests with those of shareholders.
• The immediate vesting of the Restricted Stock Units (RSUs) indicates a direct and immediate increase in Mr. Glass's stake in the company.

Future Outlook

The filing does not contain any forward-looking statements or guidance.

Industry Context

This transaction represents routine insider equity compensation, common across various industries, including technology and healthcare, to incentivize and retain key executives and directors. It reflects a standard practice of aligning management's financial interests with the long-term performance of the company.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) as a form of equity compensation is a widely adopted practice in public companies, comparable to compensation structures seen in firms like Pfizer (PFE) or Johnson & Johnson (JNJ) for their medical officers, though the scale of the grant would vary significantly based on company size and executive role.
• Immediate vesting of RSUs, while less common than phased vesting, is sometimes used for specific grants or as part of a broader compensation strategy, similar to practices observed in some smaller biotech or tech firms aiming to provide immediate equity stake.

Related Party Transactions

• The grant of Restricted Stock Units to Mitchell Glass, a Director and Chief Medical Officer, constitutes a related party transaction as it involves compensation from the company to an executive.

Stakeholder Impact

• Shareholders: Increased alignment of management's interests with shareholders due to higher insider ownership.
• Employees: May signal stability in executive leadership and a standard approach to executive compensation.

Key Dates

Keywords

Q/C Technologies, QCLS, Mitchell Glass, Insider Trading, Form 4, Restricted Stock Units, RSU Grant, Director, Chief Medical Officer, Equity Compensation